Merck
  • Home
  • Search Results
  • High percentage of regulatory T cells before and after vitamin B12 treatment in patients with pernicious anemia.

High percentage of regulatory T cells before and after vitamin B12 treatment in patients with pernicious anemia.

Acta haematologica (2014-08-30)
Satoru Watanabe, Norifumi Ide, Hatsue Ogawara, Akihiko Yokohama, Takeki Mitsui, Hiroshi Handa, Hiromi Koiso, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami
ABSTRACT

In some previous studies, vitamin B12 treatment showed immunomodulatory effects and restored the immunological abnormalities in patients with pernicious anemia (PA). In the present study, peripheral blood T cell subsets, including regulatory T cells (T(reg)s), were examined before and after vitamin B12 treatment in PA patients. The percentages of CD4, CD8, Th1, Th2 and T(reg)s were examined in 23 PA patients before vitamin B12 treatment, in 23 other PA patients after vitamin B12 treatment and in 28 healthy controls. The mean percentage of CD8+ T cells was significantly higher in the control group (23.0%; 95% CI, 20.4-25.6%) than in the pre- (16.0%; 95% CI, 12.1-20.0%) and posttreatment groups (15.2%; 95% CI, 11.8-18.6%; p < 0.05). The CD4/CD8 ratio was significantly lower in the control group (2.01; 95% CI, 1.66-2.34) than in the pre- (3.45; 95% CI, 2.55-7.80) and posttreatment groups (2.97; 95% CI, 2.22-3.72; p < 0.05). There was no significant difference in the mean Th1/Th2 ratio among these groups. There were significant increases in the mean percentage of T(reg)s in the pre- (6.29%; 95% CI, 5.04-7.54%) and posttreatment groups (7.77%; 95% CI, 6.34-9.20%) compared with the control group (4.18%; 95% CI, 3.92-4.47%; p < 0.05). The percentage of T(reg)s was significantly higher in PA patients than in normal subjects, and this high T(reg) percentage was not different before and after vitamin B12 treatment. Other immunological alterations also did not recover after vitamin B12 treatment, so that these immunological changes appear to be the cause of PA and are not induced by vitamin B12 deficiency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cyanocobalamin, tested according to Ph. Eur.
Sigma-Aldrich
Cyanocobalamin, meets USP testing specifications
Sigma-Aldrich
Cyanocobalamin, SAJ special grade, ≥95.0%
Sigma-Aldrich
Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-16, purified immunoglobulin, buffered aqueous solution
Supelco
Cyanocobalamin (B12), analytical standard
Supelco
Cyanocobalamin (Vitamin B12) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Cyanocobalamin, European Pharmacopoeia (EP) Reference Standard
Supelco
Cyanocobalamin, pharmaceutical secondary standard, certified reference material
Sigma-Aldrich
Monoclonal Anti-CD4 antibody produced in mouse, clone OX-35, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-CD4 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0395, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Vitamin B12, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Vitamin B12, ≥98%
Sigma-Aldrich
Anti-CD4 antibody, Mouse monoclonal, clone Q4120, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-CD4 , (N-terminal) antibody produced in mouse, clone MEM-241, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-CD4 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution